1. A comprehensive study of polymorphisms inABCB1, ABCC2andABCG2and lung cancer chemotherapy response and prognosis
- Author
-
Lutz Edler, Roberto Barale, Phillip Müller, Federico Canzian, Angela Risch, Daniele Campa, Lena Franziska Knoefel, Michael Thomas, and Claus Peter Heussel
- Subjects
Male ,Oncology ,Cancer Research ,Candidate gene ,medicine.medical_specialty ,ATP Binding Cassette Transporter, Subfamily B ,Lung Neoplasms ,ABCG2 ,medicine.medical_treatment ,Antineoplastic Agents ,ABCC2 ,Treatment of lung cancer ,Biology ,survival ,Lung cancer, ABCB1, ABCC2, ABCG2, survival, pharmacogenetics ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Carcinoma ,medicine ,ATP Binding Cassette Transporter, Subfamily G, Member 2 ,Humans ,ATP Binding Cassette Transporter, Subfamily B, Member 1 ,Carcinoma, Small Cell ,Lung cancer ,neoplasms ,pharmacogenetics ,Chemotherapy ,Polymorphism, Genetic ,Genetic heterogeneity ,ABCB1 ,Middle Aged ,Prognosis ,medicine.disease ,Multidrug Resistance-Associated Protein 2 ,Neoplasm Proteins ,respiratory tract diseases ,Haplotypes ,ATP-Binding Cassette Transporters ,Female ,Small Cell Lung Carcinoma ,Multidrug Resistance-Associated Proteins ,Pharmacogenetics - Abstract
ATP-binding cassette (ABC) transporter expression and genetic heterogeneity have been implicated in response to anticancer therapy. This study characterized genetic variability of the ABCB1 (also known as MDR1), ABCC2 (MRP2) and ABCG2 (BCRP) genes, which are key players in the metabolism of many chemotherapeutic agents including those used in the treatment of lung cancer. We genotyped 53 polymorphisms in the candidate genes in genomic DNA samples of 171 cases of small cell lung carcinoma (SCLC) and 206 cases of non-small cell lung carcinoma (NSCLC), and studied their impact on early response to chemotherapy, progression-free survival and overall survival. SNP rs717620 in ABCC2 was moderately associated with a poor response to chemotherapy but strongly with shorter progression-free survival and overall survival in SCLC but not NSCLC patients, indicating that ABCC2 genetic variation is an important factor in SCLC survival after chemotherapy.
- Published
- 2012
- Full Text
- View/download PDF